

EXPRESS MAILING

EL 072 043 US

**INFORMATION
DISCLOSURE STATEMENT**

Address to:
Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

	Attorney Docket Confirmation No.	RICE-006 Not Yet Assigned
	First Named Inventor	Little
	Intl. Application Number	PCT/AU00/00982
	Intl. Filing Date	August 17, 2000
	Priority Date Claimed	August 19, 1999
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Title	Drug For Treating Fractures

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefore RICE-006.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: February 12, 2002

By: 

Alan W. Cannon
Registration No. 34,977

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231
F:\DOCUMENT\GUID\028\IDS - before 1st OA1.doc

10704956

JC13 Rec'd PCT/PTO 12 FEB 2002

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Attorney Docket Number	RICE-006

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
B1	WO	93/11786		Procter & Gamble Pharmaceuticals, Inc.	06/24/1993	
B2	WO	94/21266		Leiras Oy	09/24/1994	
B3	WO	95/28936		Merck & Co., Inc.	11/02/1995	
B45	WO	96/39150		Merck & Co., Inc.	12/12/1996	
B5	WO	96/39151		Merck & Co., Inc.	12/12/1996	
B6	WO	98/00438		The University of Liverpool	01/08/1998	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
		T ²				

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.